Galectin Therapeutics Inc. (GALT)

[thefamilyman]

I agree that it is in those two documents you referenced. However, it is not mentioned in the 10-Q which is where oldsport stated it could be found.

My comments were based on the 11/9/14 PR which seemed to indicate that "digital morphometric analysis" was a "non-invasive" measure. I got that from the sentence that followed "digital morphometric analysis" which started with "Additional non-invasive measures". That phraseology seemed to indicate that "digital morphometric analysis" was "non-invasive" and therefore could not be a biopsy.

Most investors would not know, as I did not know, that "digital morphometric analysis" (DMA) is done via biopsy. Apparently someone pointed that out them because, as you indicated, the information put out today does specifically indicate that DMA is accomplished via biopsy. This is another example of how our management team does not do a good job of clear and timely communication with the investment community. Part of the problem is that their PR's sound like the target audience is the scientific community as opposed to the investment community.

"The company is planning to initiate a Phase 2 clinical trial in the second quarter of 2015 based on the robust pre-clinical effects of the drug and these successful Phase 1 results," said Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics. "Following a recent meeting with the U.S. Food and Drug Administration, the company has determined its Phase 2 trial will be in NASH patients with cirrhosis with evaluation of portal hypertension (hepatic venous pressure gradient) as the primary surrogate endpoint and the amount of collagen, as determined by digital morphometric analysis, as a key secondary endpoint. Additional non-invasive measures of liver function and structure will also be assessed." - From the 11/9/14 PR